Table 1.
Individual characteristics and results of eligible prognostic studies evaluating survival
| First Author | CD44 type | Year | Ethnicity | case | Method | Cutt off value | Univariate HR | Univariate 95% CI | Muti-variate HR | Muti-variate 95% CI | SCC/ADC/Others | Stage (I/II/III/IV) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clarke MR | pan-CD44 | 1995 | America | 31 | IHC | > 0% | 0.45 | 0.28-0.73 | NA | NA | NA | 31/0/0/0 |
| Hirata T | CD44-V6 | 1998 | Japan | 69 | IHC | ≥ 20% | 2.42 | 0.91-6.43 | 2.55 | 1.31-4.98 | 25/43/1 | 69/0/0/0 |
| Fukuse T | CD44-V6 | 1999 | Japan | 34 | IHC | ≥ 20% | 0.95 | 0.50-1.81 | 0.29 | 0.05-1.63 | 12/21/1 | NA |
| Pirinen R | CD44-V6 | 2000 | Finlang | 231 | IHC | > 66% | NA | NA | 2 | 1.20-3.0 | 146/58/27 | 149/78/0/0 |
| Ramasami S | CD44-V6 | 2000 | UK | 120 | IHC | ≥ 10% | 0.59 | 0.40-0.87 | NA | NA | 0/120/0 | 69/35/16/0 |
| Zhang HZ | CD44-V6 | 2001 | China | 42 | IHC | > 0% | 1.59 | 0.92-2.75 | NA | NA | 15/27/0 | 25/12/4/1 |
| Zhang GR | CD44-V6 | 2003 | China | 62 | IHC | ≥ 10% | 2.81 | 1.75-4.51 | NA | NA | 33/29/0 | 9/26/27/0 |
| Zhang YC | CD44-V6 | 2003 | China | 79 | IHC | > 0% | 0.82 | 0.48-1.42 | NA | NA | 42/37/0 | 32/32/15/0 |
| Cheng C | pan-CD44 | 2004 | China | 32 | IHC | > 0% | NA | NA | 1.217 | 0.054-2.87 | 19/12/1 | 0/0/32/0 |
| Zhang L | CD44-V6 | 2004 | China | 43 | IHC | ≥ 10% | 3.2 | 1.59-6.45 | NA | NA | 24/19/0 | 17/12/14/0 |
| Liu B | CD44-V6 | 2005 | China | 108 | IHC | > 4 score | 1.5 | 1.13-1.98 | NA | NA | 56/44/8 | NA |
| Wu QP | CD44-V6 | 2005 | China | 52 | IHC | > 0% | 1.53 | 0.92-2.53 | 1.88 | 1.15-2.76 | 31/21/0 | 19/20/12/1 |
| Le QT | CD44-V6 | 2006 | Ireland | 20 | IHC | > 0% | 1.98 | 0.56-6.95 | NA | NA | 2/10/8 | 12/8/0/0 |
| Li GH | pan-CD44 | 2007 | China | 36 | RT-PCR | NA | 2.15 | 0.95-4.85 | NA | NA | 19/13/4 | 25/0/11/0 |
| Weng MX | CD44-V6 | 2008 | China | 86 | IHC | > 5 score | 1.68 | 1.32-2.14 | NA | NA | 50/36/0 | 47/18/21/0 |
| Xie ZM | CD44-V6 | 2008 | China | 80 | IHC | > 0% | NA | NA | 1.87 | 0.298-4.72 | 28/52/0 | 80/0/0/0 |
| Wu Y | pan-CD44 | 2009 | China | 36 | RT-PCR | > 0.5 | 1.11 | 0.24-5.13 | NA | NA | 7/19/2 | 12/0/9/0 |
| Zhang XH | CD44-V6 | 2009 | China | 46 | IHC | > 0% | 2.43 | 1.11-5.32 | NA | NA | 15/27/4 | NA |
| Meng L | CD44-V6 | 2010 | China | 56 | IHC | ≥10% | 3.41 | 2.08-5.57 | NA | NA | 32/24/0 | 22/34/0/0 |
| Situ DR | CD44-V6 | 2010 | China | 190 | IHC | > 0% | 0.318 | 0.14-0.15 | 0.325 | 0.14-0.77 | 71/60/59 | 190/0/0/0 |
| Ko YH | pan-CD44 | 2011 | South Korea | 82 | IHC | > 3 score | 3.32 | 2.12-5.2 | 3.152 | 1.26-7.91 | 0/82/0 | 43/18/21/0 |
| Wei MC | CD44-V6 | 2011 | China | 60 | IHC | ≥ 4 score | 3.03 | 1.70-5.41 | NA | NA | 33/27/0 | 60/0/0/0 |
| Okudela K | pan-CD44 | 2012 | Japan | 177 | IHC | ≥ 10% | 2.29 | 0.89-5.90 | 3.73 | 1.2-11.58 | NA | 177/0/0/0 |
Abbreviation: P/N, positive expression/negative expression; IHC, immunohistochemistry; SCC, Squamous cell carcinoma; ADC, Adenocarcinoma; HR, hazard ratio; NA, no available or no applicable.